Aspen Neuroscience (NASDAQ:ASPE) Major Shareholder Venture Fund L.P. Arch Purchases 133,333 Shares of Stock

Aspen Neuroscience, Inc. (NASDAQ:ASPE) major shareholder Venture Fund L.P. Arch purchased 133,333 shares of the firm’s stock in a transaction on Monday, November 2nd. The stock was bought at an average price of $15.00 per share, for a total transaction of $1,999,995.00. Following the acquisition, the insider owned 66,667 shares in the company, valued at $1,000,005. The trade was a -200.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Aspen Neuroscience Trading Down 12.4%

Shares of ASPE stock opened at $13.04 on Tuesday. Aspen Neuroscience, Inc. has a 1-year low of $11.60 and a 1-year high of $14.90.

Aspen Neuroscience, Inc is a biotechnology company focused on developing regenerative medicine therapies for neurological disorders. The company’s approach uses a patient’s own cells to create induced pluripotent stem cells, which are then differentiated into specialized cells intended to replace damaged or lost tissue.

Aspen’s lead program, ANPD001, is designed as a potential cell replacement therapy for Parkinson’s disease. The company has also developed genetic screening and manufacturing processes intended to evaluate a patient’s cells and produce an individualized therapeutic product.

Aspen Neuroscience is headquartered in San Diego, California.